Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer

NCT04220775 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped The sponsor decided to no longer develop the drug and stop support of studies using the drug.

Conditions

Recurrent Head and Neck Squamous Cell Carcinoma
Second Primary Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Bintrafusp Alfa
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration
RADIATION: Stereotactic Body Radiation Therapy

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]